

# Exercise of warrants of series TO 2

Diagonal Bio AB

## IMPORTANT INFORMATION

This information material has been prepared by Diagonal Bio AB ("Diagonal Bio" or the "Company"). Investors are encouraged to read the memorandum published by the Company in January 2025 in connection with the rights issue of units whereby warrants of series TO 2 were issued. The memorandum, which contains a description of the risk factors associated with an investment in the Company, is available for download on the Company's website: [www.diagonalbio.com](http://www.diagonalbio.com).

**Exercise period:**  
4-18 june 2025



## Diagonal Bio revolutionises diagnostics with a patented technology that challenges PCR in speed, accuracy and cost efficiency – poised for scalable growth in a multi-billion market.

Despite significant progress in the diagnostic industry, there is still a lack of rapid and reliable tools to identify viral infections at an early stage. Traditional diagnostic methods such as PCR, while accurate, are time-consuming, require sophisticated laboratories, and are costly. This means a long wait for the test result, increasing the risk of spread of infection.

Since the Company's inception in 2020, our vision has been to limit the spread of infectious diseases through fast, reliable and user-friendly on-site diagnostics. Using our patented platform technology, we have developed two product families, LAMPlify and PANVIRAL, which have the potential to transform the way viruses and bacteria are identified – both in healthcare and other important application areas such as veterinary medicine, food safety and agriculture.

With a continued focus on commercial pilots and partnerships, we have taken important steps towards market acceptance. Our 2025 target is to significantly increase the number of units in operation and convert a large proportion of our pilot tests into repeat customers. We are also continuously working to expand our offering with new viruses, i.e. genetic markers. Due to the focused investment in LAMPlify, we have chosen to temporarily pause the regulatory work with PANVIRAL to concentrate resources on fully commercialising LAMPlify.

Our technology combines the diagnostic accuracy previously reserved for centralised laboratories, with the simplicity and speed required to make the right decisions close to the patient – whether in a stable, veterinary clinic or laboratory. With a growing global market, a clear business and distribution focus, and a proven technology platform, we look to the future with confidence.

The warrants of series TO 2 give us the opportunity to further accelerate our efforts. The capital will be used to strengthen our commercialisation of LAMPlify through marketing, sales and production. Together with our partners and investors, we are determined to build a strong, internationally competitive diagnostics company.

We thank you for your trust and look forward to continuing the journey together.



**Karin Wehlin**  
CEO, Diagonal Bio AB



**"With a growing global market, a clear business and distribution focus, and a proven technology platform, we look to the future with confidence."**

**Karin Wehlin**  
CEO, Diagonal Bio AB





# Investment highlights



## Patented high-accuracy platform technology

Diagonal Bio's technology matches the accuracy of the PCR-based technologies – but is faster, simpler and more cost-effective.



## Commercial launch

LAMPlify is in active pilot phase with a view to market acceptance in 2025; a total of 30 units are expected to be delivered during the year.



## Focus on commercialisation

The proceeds from TO 2 will finance commercialisation and production – with a clear focus on growth.



## Strong market potential in multiple segments

LAMPlify targets veterinary, agricultural and laboratory markets – a global PCR market valued at USD 9bn.



## Scalable revenue model

The business model allows for recurring revenue via sales of consumables after initial installation of instruments.



**Diagonal Bio** is a Swedish biotech company founded in 2020 with the vision to limit the spread of infectious diseases by creating a **fast, user-friendly, cost-effective diagnostic platform with high accuracy.**

Based on a patented platform technology, Diagonal Bio is developing analytical instruments that have the potential to meet the challenge of quickly and accurately identifying genetic markers for infectious diseases. Diagonal Bio was listed on Nasdaq First North Growth Market on 16 July 2021 and transferred to NGM Nordic SME on 19 March 2025.

Diagonal Bio's technology offers the same accuracy as today's leading analysis method – PCR – but without being dependent on complex logistics or large central laboratories.

The Company's technology enables the analysis of current and future infectious diseases within 10–15 minutes of sample collection. The applications of Diagonal Bio's technology also extend beyond the in vitro diagnostics market segment, such as the identification of bacteria in food, feed and water or the detection of pests, pathogens and diseases in animals and crops, all with the same high accuracy as current PCR-based techniques but faster, easier and more cost-effective.

# Diagonal Bio is developing two product families based on the patented platform technology

## – LAMPlify and PANVIRAL

LAMPlify is designed for less regulated market segments as a customised system for general laboratory and veterinary use. PANVIRAL is tailored for the in vitro diagnostics market segments and has the potential to revolutionise healthcare and significantly improve the fight against the spread of infectious diseases.

### LAMPlify® and PANVIRAL®

The spread of respiratory viruses, for example, is rapid, and rapid analysis results are required to minimise the spread. The current solution means that the logistics chain together with the analysis rarely provides answers within 48 hours.



### LAMPlify®

**LAMPlify** is used to within 10-15 minutes identify the presence of specific genetic markers, e.g. for viruses, bacteria and fungi. As a user-friendly, portable, fast and accurate molecular diagnostic instrument that can analyse up to eight different tests simultaneously, it is suitable for use in both field and laboratory settings.



### PANVIRAL®

Designed for human diagnostics, **PANVIRAL** can be customised to detect different types of infectious diseases, enabling fast, accurate, cost-effective and parallel diagnosis. With the potential to reduce analysis time to up to 10-15 minutes, the product can be used in diagnostic laboratories as well as in point-of-care analyses. PANVIRAL can analyse up to eight different tests simultaneously.

## Market potential

LAMPlify addresses markets that include general laboratory and veterinary diagnostics, where PCR-based methods have traditionally been used to identify genetic markers. The global market for PCR-based methods is valued at approximately USD 9 billion and is expected to grow to USD 13.75 billion by 2028. The goal is to position LAMPlify in this market as a fast, reliable and cost-effective method for identifying genetic markers.

The Company aims to revolutionise infectious disease diagnostics through large-scale, cost-effective and accurate diagnostic products. Targeting the fast-growing in vitro diagnostics market, expected to reach USD 106bn by 2030, where over 70% of healthcare decisions are influenced by diagnostic tests, PANVIRAL is designed for rapid and accurate detection of pathogenic diseases.

Diagonal Bio is currently focusing its efforts on commercialising LAMPlify. The road to market for PANVIRAL is associated with additional regulatory investments to achieve CE marking according to EU-IVDR and/or US-FDA before market launch can be initiated, which is why further investments in PANVIRAL are paused and all resources are devoted to commercialising LAMPlify. By offering pilot tests to Key Opinion Leaders (KOLs) and various end-users, the Company not only receives valuable feedback from users on results and performance, but also helps to spread knowledge about the Company and its technology.

## Business and revenue model

Diagonal Bio aims to build a small commercial organisation and/or establish partnerships with existing distributors or larger market players for the launch of LAMPlify and later PANVIRAL. The Company plans to target the initial commercialisation of LAMPlify towards selected market segments in the equine, veterinary, fish farming, pig production and general research laboratory testing segments. Diagonal Bio is currently focusing its initial efforts on partnerships or licence agreements with distributors, Key Opinion Leaders (KOLs) and market collaborators for the launch of LAMPlify, and at a later stage PANVIRAL.

Diagonal Bio plans to commercialise LAMPlify using the 'razor-blade model', selling or leasing instruments at a relatively low cost while generating recurring revenue through sales of proprietary consumables. These consumables, which include cassettes and reagents for the identification of specific genetic material, are necessary to operate the instruments. Over time, Diagonal intends to develop a portfolio of several reagents, each specific to the identification of different genetic markers. These reagents will then be sold to a growing number of customers.

## Objective

Diagonal Bio's overall target for 2025 is, in addition to the ten LAMPlify platforms delivered in 2024, to deliver a further 30 to end-users, thereby achieving market acceptance. The Company expects to convert 50 percent of the 40 LAMPlify platforms from pilot testing to sales.

### Summary of the offering

**Exercise period:**

4-18 June 2025.

**Exercise price:**

SEK 0.01 SEK per share.

**Issue volume:**

Diagonal Bio will through warrants of series TO 2 receive approximately SEK 3.6 million.

**Pre-subscription and underwriting**

**commitments:** the warrants are secured to 100 percent through pre-subscription (from the board members and the CEO as well as an external warrant holder) and underwriting commitments. For the underwriting commitment, a compensation of 18 percent in the form of shares, to the same terms as in the warrant exercise, will be paid.

**Last day of trading in TO 2:**

16 June 2025.

### Use of proceeds

The proceeds that the Company can receive through the exercise of warrants of series TO 2 are, like the rights issue in January 2025, intended to provide the Company with resources to focus on validating LAMPlify's commercial interest in the equine segment. This will be achieved by reaching the goals set by the Company regarding the initiation of new pilot projects and results from completed pilot projects, with the overall goal of achieving market acceptance by the end of 2025. The proceeds are intended to finance the production of instruments and consumables, sales and marketing, intellectual property and working capital.



# Summarised terms for TO 2

There are 361,889,384 outstanding warrants of series TO 2. Holders of warrants of series TO 2 are entitled to subscribe for one (1) new share in Diagonal Bio at a price of SEK 0.01 per share for each one (1) warrant of series TO 2. Subscription by the exercise of warrants of series TO 2 may take place during the period from 4 June 2025 up to and including 18 June 2025. Subscription shall be made by simultaneous cash payment no later than 17:00 on 18 June 2025.

## You need to consider the offer as a warrant holder – this is how you exercise your warrants of series TO 2

In order for your warrants not to expire worthless, you must subscribe for new shares, with the support of warrants, no later than 17:00 on 18 June 2025, or sell your warrants no later than 16 June 2025.

You can have your warrants registered in two ways:

1. in a securities depository account with a bank or other nominee (e.g. Avanza or Nordnet), in an investment savings account (ISK) or in an endowment insurance (KF). Your warrants are then nominee-registered.
2. in a securities account. Your warrants are then directly registered.

## Warrants that are nominee registered

Subscription and payment for new shares, by virtue of warrants, shall be made to the respective bank or other nominee where the warrants are registered. Subscription and payment shall be made in accordance with the instructions provided by each such bank or nominee. Usually the bank/trustee will send out a digital notice to the account holder, otherwise it is usually sufficient to log in to the securities depository from the first day of the exercise period to receive instructions on how to exercise warrants to subscribe for new shares. Please contact your bank or nominee if you cannot find these instructions.

Please note that banks and other nominees may set different time limits for subscription, therefore it is recommended that you contact your bank/nominee early in the exercise period to obtain information on subscription and payment. Subscribed and paid shares may be registered in your securities depository account as 'interim shares' or 'IA' until registration of the issue is completed with the Swedish Companies Registration Office, whereupon interim shares are automatically converted into ordinary shares in Diagonal Bio.

## Warrants that are directly registered

No issue statement will be sent out. Subscription for new shares, with the support of warrants, shall be made by submitting a fully completed application form to Aqurat Fondkommission AB via e-mail. When the application form is sent to Aqurat Fondkommission AB, payment shall be made in accordance with the payment instructions on the application form. The application form and this information sheet are available on the Company's ([www.diagonalbio.com](http://www.diagonalbio.com)) and Aqurat Fondkommission AB's website ([www.aqurat.se](http://www.aqurat.se)).

The completed application form and payment must be received by Aqurat Fondkommission AB no later than 17:00 on 18 June 2025. Subscribed and paid shares will be registered on your securities account as 'interim shares' or 'IA' until registration of the issue is completed with the Swedish Companies Registration Office, whereupon interim shares will automatically be converted into ordinary shares in Diagonal Bio.

## Subscription over EUR 15,000 where applicable

In the event that your subscription amounts to or exceeds EUR 15,000, a money laundering form must be completed and submitted to Aqurat Fondkommission AB in accordance with the Swedish Act (2017:630) on Measures against Money Laundering and Terrorist Financing, at the same time as payment is made. Please note that interim shares cannot be booked out, even though payment has been received, until the money laundering control is received by Aqurat Fondkommission AB. Money laundering forms are available from Aqurat Fondkommission AB.

## Important dates for warrants of series TO 2

**4 June 2025** – exercise period starts

**16 June 2025** – last day of trading in warrants

**18 June 2025** – exercise period ends

**19 June 2025** – planned date of announcement of outcome

**Around 2 July 2025** – conversion of interim shares into shares

**NOTE** – In order for your warrants not to expire worthless, you are required to actively subscribe and pay for shares no later than 17:00 on 18 June 2025, or alternatively sell your warrants no later than 16 June 2025. If you have any questions regarding warrants of series TO 2, please contact Navia Corporate Finance AB or Aqurat Fondkommission AB. Navia Corporate Finance AB and Aqurat Fondkommission AB are acting as financial advisor and issuing agent, respectively, to Diagonal Bio in connection with the exercise of warrants. Setterwalls Advokatbyrå is acting as legal advisor.

*For full details of the offer, please refer to the memorandum published by the Company in January 2025.*